Panacea will then supply the doses to drugmaker Dr. Reddy's Laboratories for distribution in India. (https://bit.ly/3joeloz)
(Reporting by Anuron Kumar Mitra in Bengaluru; Editing by Shailesh Kuber)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
137.2 INR | -0.72% | -2.94% | -18.39% |
BENGALURU (Reuters) - India's Panacea Biotec Ltd said on Thursday it had agreed to produce up to 25 million doses of the Sputnik V COVID-19 vaccine using the drug substance made by Russia's Generium.
Panacea will then supply the doses to drugmaker Dr. Reddy's Laboratories for distribution in India. (https://bit.ly/3joeloz)
(Reporting by Anuron Kumar Mitra in Bengaluru; Editing by Shailesh Kuber)
1st Jan change | Capi. | |
---|---|---|
+20.83% | 43.57B | |
+20.70% | 22.7B | |
+16.41% | 14.32B | |
+11.11% | 13.42B | |
+45.91% | 11.83B | |
-8.84% | 6.98B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+12.41% | 5.51B |